Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887013 | 0.87 | TTK (0.40) | TTKMAPK8THRBLMNAMAPT | |
| SCHEMBL5887244 | 0.87 | MAPK14 (0.44) | KMT2AMEN1ALDH1A1TTKMAPK8 | |
| SCHEMBL5887259 | 0.86 | PARP10 (0.39) | KMT2AMEN1ALDH1A1PKMAPLNR | |
| SCHEMBL5886782 | 0.85 | PDE4B (0.44) | TTKMAPK8THRBMAPTPDE4B | |
| SCHEMBL5887588 | 0.84 | SMN1; SMN2 (0.42) | KMT2AMEN1ALDH1A1TTKMAPK8 | |
| SCHEMBL5887451 | 0.83 | MAPK8 (0.42) | ALDH1A1TTKMAPK8THRBLMNA | |
| SCHEMBL5887438 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPT | |
| SCHEMBL5887062 | 0.77 | SMYD3 (0.43) | KMT2AMEN1ALDH1A1PKMMAPK8 | |
| SCHEMBL5887454 | 0.77 | PDE4B (0.38) | TTKMAPK8THRBLMNAMAPT | |
| SCHEMBL5886823 | 0.75 | SMYD3 (0.48) | KMT2AMAPK8LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | KMT2A 1530/4885MEN1 2183/4885ALDH1A1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.